Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 0.67 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.60 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.60 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.60 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.60 |
| ▸ | RHOA | P61586 | 1/20 | 0.58 |
| ▸ | PTGES | O14684 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18832326 | 0.87 | GUCY1B2 (0.65) | ABCG2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL19129498 | 0.86 | GUCY1B2 (0.71) | ABCG2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL22860728 | 0.84 | GUCY1B2 (0.64) | ABCG2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL19129482 | 0.83 | GUCY1B2 (0.64) | ABCG2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL19129620 | 0.83 | GUCY1B2 (0.55) | ABCG2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL2843230 | 0.82 | KDM4E (0.65) | ABCG2PTGESALOX5MAPTNPC1 | |
| SCHEMBL17597920 | 0.82 | GUCY1B2 (0.73) | ABCG2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL17598175 | 0.82 | GUCY1B2 (0.76) | ABCG2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL8901888 | 0.81 | ABCG2 (0.76) | ABCG2 | |
| SCHEMBL22860661 | 0.81 | EGFR (0.67) | ABCG2GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204071-A1 | ARYL AMINE SUBSTITUTED QUINOXALINE USED AS ANTICANCER DRUGS | SHIAU, CHUNG-WAI (TW) | 2017-07-20 | — | — | US | disclosed |
| US-20170204071-A1 | ARYL AMINE SUBSTITUTED QUINOXALINE USED AS ANTICANCER DRUGS | SHIAU, CHUNG-WAI (TW) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204071-A1 | ARYL AMINE SUBSTITUTED QUINOXALINE USED AS ANTICANCER DRUGS | CIP2A, PPP2CA, PPM1A | ABCG2 2731/4885GUCY1B2 3821/4885GUCY1A2 3430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.